Evaluation of an 111in-radiolabeled peptide as a targeting and imaging agent for ErbB-2 receptor-expressing breast carcinomas

Clinical Cancer Research

Volumn 13, Issue 20, 2007, Pages 6070-6079

  Kumar, Senthil R ^a   Quinn, Thomas P ^a   Deutscher, Susan L ^a,b  

^a University of Missouri   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID (GLYCYLSERYLGLYCYL)LYSYLCYSTEINYLCYSTEINYLTYROSYLSERYLLEUCINE IN 111; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID (GLYCYLSERYLGLYCYL)LYSYLTYROSYLLEUCYLCYSTEINYLSERYLCYSTEINE IN 111; ALANINE; BIOTIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INDIUM 111; LYSYLCYSTEINYLCYSTEINYLTYROSYLSERYLLEUCINE; PEPTIDE; UNCLASSIFIED DRUG; CONTRAST MEDIUM; INDIUM; RECOMBINANT PROTEIN;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIOPHAGE; BINDING AFFINITY; BINDING SITE; BREAST CARCINOMA; CANCER DIAGNOSIS; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; EXTRACELLULAR SPACE; FLUORESCENCE; HUMAN; HUMAN CELL; INTERNALIZATION; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN TARGETING; RADIOACTIVITY; RADIOASSAY; SCID MOUSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; XENOGRAFT; ANIMAL; BREAST TUMOR; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; GENE EXPRESSION REGULATION; IC 50; METABOLISM; METHODOLOGY; MOUSE MUTANT; SCINTISCANNING; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CONTRAST MEDIA; DIAGNOSTIC IMAGING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDIUM RADIOISOTOPES; INHIBITORY CONCENTRATION 50; MICE; MICE, SCID; MICROSCOPY, CONFOCAL; PEPTIDES; RECEPTOR, ERBB-2; RECOMBINANT PROTEINS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 35948968807     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0160     Document Type: Article

References (45)

1. Tsongalis GJ, Ricci A, Jr. Breast cancer as a model of realistic challenges in pharmacogenomics. Clin Biochem 2003;36:89-94.
2. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. The Oncologist 1998;3:237-52.
3. McInnes C, Sykes BD. Growth factor receptors: structure, mechanism, and drug discovery. Biopolymers 1997;43:339-66.
4. Ross JS, Fletcher JA. The Her-2/neu oncogene. prognostic factor, predictive factor and target for therapy. Semin Cancer Biol 1999;9:125-38.
5. Jones JT, Akita RW, Sliwkowski MX. Binding specificities and affinities of EGF domains for ErbB receptors. FEBS Lett 1999;447:227-31.
6. Taupin D, Wu DC, Jeon WK, et al. The trefoil gene family are coordinately expressed immediate-early genes: EGF receptor- and MAP kinase-dependent interregulation. J Clin Invest 1999;103:R31-8.
7. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-67.
8. De Potter CR, Van Daele S, Van de Vijver MJ, et al. The expression of the neu oncogene product in breast lesions and in normal fetal and adult human tissues. Histopathology 1989;15:351-62.
9. Weiner LM, Clark JI, Davey M, et al. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and FcγRIII. Cancer Res1995;55:4586-93.
10. Jinno H, Ueda M, Enomoto K, et al. Effectiveness of an Adriamycin immunoconjugate that recognizes the C-erbB-2 product on breast cancer cell lines. Surg Today 1996;26:501-7.
11. Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 1999;5:1289-97.
12. Harris JD, Gutierrez AA, Hurst HC, Sikora K, Lemoine NR. Gene therapy for cancer using tumour-specific prodrug activation. Gene Ther 1994;1:170-5.
13. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58:2825-31.
14. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.
15. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20:1215-21.
16. Fischman AJ, Babich JW, Strauss HW. A ticket to ride: peptide Radiopharmaceuticals. J Nucl Med 1993;34:2253-63.
17. Landon LA, Zou J, Deutscher SL. Is phage display technology on target for developing peptide-based cancer drugs ? Curr Drug Discov Technol 2004;1:113-32.
18. 111In-DTPA-D-Phe-1]-octreotide for detection of somatostatin receptor-positive tumors in rats. Life Sci 1991;49:1593-601.
19. 188Re-labeled α-melanocyte stimulating hormone peptide analogs for melanoma therapy. Int J Cancer 2002;101:480-7.
20. Doorbar J, Winter G. Isolation of a peptide antagonist to the thrombin receptor using phage display. J Mol Biol 1994;244:361-9.
21. Renschler MF, Wada HG, Fok KS, Levy R. B-lymphoma cells are activated by peptide ligands of the antigen binding receptor or by anti-idiotypic antibody to induce extracellular acidification. Cancer Res 1995;55:5642-7.
22. Murayama O, Nishida H, Sekiguchi K. Novel peptide ligands for integrin α6β1 selected from a phage display library. J Biochem Tokyo 1996;120:445-51.
23. Peletskaya EN, Glinsky G, Deutscher SL, Quinn TP. Identification of peptide sequences that bind the Thomsen-Friedenreich cancer-associated glycoantigen from bacteriophage display libraries. Mol Diversity 1996;2:13-8.
24. Peletskaya EN, Glinsky VV, Glinsky GV, Deutscher SL, Quinn TP. Characterization of peptides that bind the tumor-associated Thomsen-Friedenreich antigen selected from bacteriophage display libraries. J Mol Biol 1997;270:374-84.
25. Ballinger MD, Jones JT, Lofgren JA, et al. Selection of heregulin variants having higher affinity for the ErbB3 receptor by monovalent phage display. J Biol Chem 1998;273:11675-84.
26. Karasseva NG, Glinsky VV, Chen NX, Komatireddy R, Quinn TP. Identification and characterization of peptides that bind human ErbB-2 selected from a bacteriophage display library. J Protein Chem 2002;21:287-96.
27. Schmidt CM, Settle SL, Keene JL, et al. Characterization of spontaneous metastasis in an aggressive breast carcinoma model using flow cytometry. Clin Exp Metastasis 1999;17:537-44.
28. Kini RM, Evans HJ. A novel approach to the design of potent bioactive peptides by incorporation of proline brackets: antiplatelet effects of Arg-Gly-Asp peptides. FEBS Lett 1995;375:15-7.
29. Hynes NE, Stern DF. The biology of erbB-2/HER-2 and its role in cancer. Biochim Biophysica Acta 1994;1998:165-84.
30. Penuel E, Akita RW, Sliwkowski MX. Identification of a region within the ErB2/HER2 intracellular domain that is necessary for ligand-independent association. J Biol Chem 2002;277:28468-73.
31. Jain RK. Delivery of molecular and cellular medicine to solid tumors. J Control Release 1998;53:49-67.
32. 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. J Nucl Med 1999;40:762-7.
33. Askoxylakis V, Zitzmann S, Mier W, et al. Preclinical evaluation of the breast cancer cell-binding peptide p160. Clin Cancer Res 2005;11:6705-12.
34. 111In-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging. J Nucl Med 2004;45:485-94.
35. Hendriks BS, Opresko LK, Wiley HS, Lauffenburger DA. Quantitative analysis of HER2-mediated effect on HER2 and EGFR endocytosis: distribution of homo and heterodimers depends on relative HER2 levels. J Biol Chem 2003;278:23343-51.
36. Hommelgaard AM, Lerdrup M, van Deurs B. Association with membrane makes ErbB2 an internalization-resistant receptor. Mol Biol Cell 2004;15:1557-67.
37. Rubin I, Yarden Y. The basic biology of HER2. Ann Oncol 2001;12:S3-8.
38. 111In-labeled DOTA-conjugated antibody fragments. Bioconjugate Chem 2001;12:264-70.
39. 111In-DOTA- rhenium cyclized a-MSH analog: a novel cyclic-peptide analog with improved tumor-targeting properties. J Nucl Med 2001;42:1847-55.
40. Behr TM, Goldenberg DM, Becker WS. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 1998;25:201-12.
41. Behr TM, Sharkey RM, Juweid ME, et al. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res 1995;55:3825-34.
42. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science1998;279:377-80.
43. Kennel SJ, Mirzadeh S, Hurst GB, et al. Labeling and distribution of linear peptides identified using in vivo phage display selection for tumors. Nucl Med Biol 2000;27:815-25.
44. Zhang J, Spring H, Schwab M. Neuroblastoma tumor cell-binding peptides through random peptide phage display. Cancer Lett 2001;171:153-64.
45. Newton JR, Kelly KA, Mahmood U, Weisselder R, Deutscher SL. In vivo selection of phage for the optical imaging PC-3 human prostate carcinoma in mice. Neoplasia 2006;8:772-80.